Tagged with Growth

Pharma Paolo Marcucci, President and CEO of Kedrion Biopharma, talks about the factors behind the company’s incredible growth and its commitment to doubling exports to the US. Furthermore, he talks about the challenges and opportunities the company encountered while supporting the national health system to become self-sufficient in plasma-collection and fractionation.…

Pharma Shire Italy’s Francesco Scopesi discusses innovative medicine, rare diseases, growth drivers, global strategy, and the new trend of home care. Shire is today one of the leading biotechs delivering innovative medicines to patients with rare diseases and other specialty conditions. Could you please start by describing the company’s engagement with…

Pharma Thépenier CEO Tsuyoshi Hasuo has imparted a unique vision to internationalize the Normandy-based French company encompassing a company turnaround and a maximization of growth potential. Together with Deputy CEO, Bertrand Lasserre, Hasuo’s mission is to capitalize upon Thépenier’s unique French-Japanese background and become a major player in cosmetics and make-up.…

Pharma Janssen Czech Republic’s MD reviews his longstanding career within the company and highlights how founder Dr. Paul Janssen’s legacy still influences operations today. He also compares the Czech regulatory environment with those of its regional neighbors and finds that there is little ground for fair comparison. You have been with…

Pharma Having successfully accomplished a four-year turnaround exercise and with a fresh capital injection from a leading Italian PE firm, SIFI executive chairman Fabrizio Chines has ambitious growth objectives for the coming years, and is investing in R&D projects including the development of an ophthalmic orphan drug. The Italian pharmaceutical industry…

Pharma Bernard Fraisse of Fareva, France’s leading CMO, discusses growth, international expansion, loyalty to France, dedication to clients, and commitment to providing high quality products. Many have predicted that pharma manufacturing in France will soon die out, but instead we have seen a shift from manufacturing of large pharmaceutical groups to…

Pharma CreaPharm Group’s CEO, Eric Placet, discusses the creation of his company, ambitions for growth, and the lessons learned throughout his leadership. He also emphasizes the relevance of the size of the business in optimizing performance. For the last 20 years, you have built the CreaPharm Group to the success that…

Pharma Mr. Aldo Braca discusses the competitive CDMO landscape in Italy, the importance of nurturing a community of employees, and the optimistic growth trend for the company powered by investment and innovation. This year, BSP celebrated its ten-year anniversary, congratulations! What were the key objectives that you have accomplished since the…

Pharma Boasting a more than 14 percent growth rate in 2015, AbbVie has cemented its status as a top 20 pharmaceutical company in France. Sharing the unique relationship the company has with France, general manager Jerome Bouyer offers an optimistic view of how the French healthcare sector can best be structured…

Pharma Eva Pharma is one of the fastest growing pharmaceutical companies in the MENA region, and CEO Riad Armanious is aiming to take the company from the 21st ranked generic company at the regional level to third over the next five years, while building business and operations on the ground in…

Pharma Frédéric Duchesne, President & CEO of Pierre Fabre’s pharmaceuticals division, talks about the the four main pillars at the heart of Trajectoire 2018, a strategic plan approved in December 2014: improving competitiveness, renewing innovative capabilities, increasing operational excellence, and lastly, furthering international development. Mr Duchesne also reveals how in 2015…

Pharma Stéphane Thiroloix, CEO of the independent and family owned Mayoly Spindler, reveals how their vision is to become a reference company internationally in the field of gastroenterology and dermocosmetics; how already forty-five percent of their business is done overseas; and how on current projections, excluding external growth, they anticipate to…